362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

James Spicer; Åslaug Helland; Enric Carcereny; Edurne Arriola; Manuel Domine; José Trigo; Jonathan Thompson; James Strauss; Ana Granados; Enriqueta Felip; Emmett Schmidt; Michael Chisamore; Noelly Madeleine; Austin Rayford; Katherine Lorens; Abdul Siddiqui; Hani Gabra; Jaya Nautiyal; David Micklem; Matthew Krebs

doi:10.1136/jitc-2020-SITC2020.0362

362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

James Spicer, Åslaug Helland, Enric Carcereny, Edurne Arriola, Manuel Domine, José Trigo, Jonathan Thompson, James Strauss, Ana Granados, Enriqueta Felip, Emmett Schmidt, Michael Chisamore, Noelly Madeleine, Austin Rayford, Katherine Lorens, Abdul Siddiqui, Hani Gabra, Jaya Nautiyal, David Micklem, Matthew Krebs

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	A387-A387
Number of pages	1
Journal	Journal for ImmunoTherapy of Cancer
Volume	8
Issue number	Suppl 3
DOIs	https://doi.org/10.1136/jitc-2020-SITC2020.0362
Publication status	Published - 1 Nov 2020

Access to Document

10.1136/jitc-2020-SITC2020.0362

Cite this

Spicer, J., Helland, Å., Carcereny, E., Arriola, E., Domine, M., Trigo, J., Thompson, J., Strauss, J., Granados, A., Felip, E., Schmidt, E., Chisamore, M., Madeleine, N., Rayford, A., Lorens, K., Siddiqui, A., Gabra, H., Nautiyal, J., Micklem, D., & Krebs, M. (2020). 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis. Journal for ImmunoTherapy of Cancer, 8(Suppl 3), A387-A387. https://doi.org/10.1136/jitc-2020-SITC2020.0362

@article{4b1e19554a2f4ad3be467d17556ad4c6,

title = "362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis",

author = "James Spicer and {\AA}slaug Helland and Enric Carcereny and Edurne Arriola and Manuel Domine and Jos{\'e} Trigo and Jonathan Thompson and James Strauss and Ana Granados and Enriqueta Felip and Emmett Schmidt and Michael Chisamore and Noelly Madeleine and Austin Rayford and Katherine Lorens and Abdul Siddiqui and Hani Gabra and Jaya Nautiyal and David Micklem and Matthew Krebs",

year = "2020",

month = nov,

day = "1",

doi = "10.1136/jitc-2020-SITC2020.0362",

language = "English",

volume = "8",

pages = "A387--A387",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "Springer Nature",

number = "Suppl 3",

}

Spicer, J, Helland, Å, Carcereny, E, Arriola, E, Domine, M, Trigo, J, Thompson, J, Strauss, J, Granados, A, Felip, E, Schmidt, E, Chisamore, M, Madeleine, N, Rayford, A, Lorens, K, Siddiqui, A, Gabra, H, Nautiyal, J, Micklem, D & Krebs, M 2020, '362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis', Journal for ImmunoTherapy of Cancer, vol. 8, no. Suppl 3, pp. A387-A387. https://doi.org/10.1136/jitc-2020-SITC2020.0362

362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis. / Spicer, James; Helland, Åslaug; Carcereny, Enric et al.
In: Journal for ImmunoTherapy of Cancer, Vol. 8, No. Suppl 3, 01.11.2020, p. A387-A387.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis

AU - Spicer, James

AU - Helland, Åslaug

AU - Carcereny, Enric

AU - Arriola, Edurne

AU - Domine, Manuel

AU - Trigo, José

AU - Thompson, Jonathan

AU - Strauss, James

AU - Granados, Ana

AU - Felip, Enriqueta

AU - Schmidt, Emmett

AU - Chisamore, Michael

AU - Madeleine, Noelly

AU - Rayford, Austin

AU - Lorens, Katherine

AU - Siddiqui, Abdul

AU - Gabra, Hani

AU - Nautiyal, Jaya

AU - Micklem, David

AU - Krebs, Matthew

PY - 2020/11/1

Y1 - 2020/11/1

U2 - 10.1136/jitc-2020-SITC2020.0362

DO - 10.1136/jitc-2020-SITC2020.0362

M3 - Meeting Abstract

SN - 2051-1426

VL - 8

SP - A387-A387

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - Suppl 3

ER -

Spicer J, Helland Å, Carcereny E, Arriola E, Domine M, Trigo J et al. 362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis. Journal for ImmunoTherapy of Cancer. 2020 Nov 1;8(Suppl 3):A387-A387. doi: 10.1136/jitc-2020-SITC2020.0362